Ergotamine inhalation - Sheffield

Drug Profile

Ergotamine inhalation - Sheffield

Alternative Names: Tempo-ergotamine

Latest Information Update: 17 Jun 2003

Price : $50

At a glance

  • Originator Sheffield Pharmaceuticals
  • Class Antimigraines; Ergot alkaloids; Vasoconstrictors
  • Mechanism of Action Alpha adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 17 Jun 2003 Sheffield Pharmaceuticals has filed for protection under Chapter 7 bankruptcy laws
  • 17 Jun 2003 Discontinued - Clinical-Phase-Unknown for Migraine in USA (Inhalation)
  • 16 Oct 2000 A clinical study has been added to the Advances in the Treatment of Nausea and Migraine pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top